COVID-19 pandemic in North Asia

BiomeBank Appoints Ex-Ellerston Capital CIO and BlackRock North Asia Director as Chair to Accelerate Commercialisation Strategy

Retrieved on: 
Wednesday, January 19, 2022
Biotechnology, General Health, Health, Clinical Trials, Foundation, CEO, Disease, COVID-19 pandemic in North Asia, Microbiology, Company, Quality of life, TGA, Multimedia, Ecology, Board, Machine learning, Nightclub, Renewable energy, Pharmaceutical industry

BiomeBank today announces Mr Chris Hall as the new Chair for the clinical stage biotechnology company, having recently served as Chief Investment Officer of Ellerston Capital.

Key Points: 
  • BiomeBank today announces Mr Chris Hall as the new Chair for the clinical stage biotechnology company, having recently served as Chief Investment Officer of Ellerston Capital.
  • Prior to this, Mr Hall served as Managing Director of Blackrock Asset Management (North-Asia Ltd).
  • View the full release here: https://www.businesswire.com/news/home/20220119005391/en/
    Mr Hall succeeds Dr Stephen Rodda, who recently retired having served as the BiomeBank Chair since 2019.
  • BiomeBank Chief Executive Officer, Mr Thomas Mitchell said: Were thrilled to welcome Mr Hall as the new Chair of BiomeBank.